Valion Bio (VBIO) Non-Current Assets (2021 - 2026)
Valion Bio (VBIO) posted quarterly Non-Current Assets of $18.6 million for Q4 2025, up 10972.02% year-over-year from N/an in Q4 2024, and up 647.33% quarter-over-quarter from $2.5 million in Q3 2025.
Valion Bio (VBIO) Non-Current Assets (2021 - 2026) Analysis & Trends
Valion Bio's Non-Current Assets history runs 5 years deep, the most recent figure standing at $18.6 million for Q4 2025.
- In Q4 2025, Non-Current Assets rose 10972.02% year-over-year to $18.6 million; the TTM figure through Dec 2025 stood at $26.3 million (up 2586.3% YoY), while the FY2025 annual figure was $18.6 million, up 10972.02% from the prior year.
- Non-Current Assets for Q4 2025 stood at $18.6 million, up from $2.5 million in the prior quarter.
- The five-year high for Non-Current Assets was $18.6 million in Q4 2025, with the low at $120000.0 in Q2 2024.
- The 5-year median for Non-Current Assets is $614000.0 (2022), against an average of $1.9 million.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets tumbled 79.87% in 2024, then soared 10972.02% in 2025.
- Valion Bio's Non-Current Assets stood at $747000.0 in 2021, then slipped by 23.83% to $569000.0 in 2022, then retreated by 11.25% to $505000.0 in 2023, then sank by 66.73% to $168000.0 in 2024, then jumped by 10972.02% to $18.6 million in 2025.
- Business Quant data shows VBIO's Non-Current Assets at $18.6 million in Q4 2025, $2.5 million in Q3 2025, and $2.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Valion Bio | 420,133.64 | -1.78 Mn | -45,000.00 | 29.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.09 Mn |
| Dec 31, 2025 | 18.60 Mn |
| Sep 30, 2025 | 2.49 Mn |
| Jun 30, 2025 | 2.67 Mn |
| Mar 31, 2025 | 2.52 Mn |
| Dec 31, 2024 | 168,000.00 |
| Sep 30, 2024 | 231,000.00 |
| Jun 30, 2024 | 120,000.00 |
| Mar 31, 2024 | 459,000.00 |
| Dec 31, 2023 | 505,000.00 |
| Sep 30, 2023 | 552,000.00 |
| Jun 30, 2023 | 596,000.00 |
| Mar 31, 2023 | 619,000.00 |
| Dec 31, 2022 | 569,000.00 |
| Sep 30, 2022 | 614,000.00 |
| Jun 30, 2022 | 654,000.00 |
| Mar 31, 2022 | 696,000.00 |
| Dec 31, 2021 | 747,000.00 |